(Reuters) – Inovio Pharmaceuticals Inc on Thursday said it partnered with non-profit organization International Vaccine Institute to begin an early trial of the U.S. biotech’s experimental COVID-19 vaccine on humans later this month.
The company said the two-stage trial, conducted in collaboration with Seoul National University Hospital, would assess the safety and effectiveness of the vaccine in 40 healthy adults, and later expand to enroll an additional 120 people.
(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli)
